Crucell: A Global Perspective
Global facilities
| Technology | Research | Development | Manufacturing | Sales & Marketing |
|---|---|---|---|---|
| Netherlands HQ | Netherlands | Netherlands | Netherlands | Netherlands (Benelux) |
| Switzerland | USA* | Switzerland | Switzerland | Switzerland |
| USA* | Sweden | Sweden (Nordic) | ||
| Spain | Spain | |||
| Korea | Italy | |||
| Korea | ||||
| China | ||||
| Indonesia | ||||
| Vietnam | ||||
| Argentina | ||||
| Canada | ||||
| USA |
- *
- PERCIVIA, a Joint Venture with DSM Biologics
We have a fully integrated infrastructure for in-house development, production and marketing of vaccines. 80+ We sell our vaccines in over 80 countries.
Products
Our vaccine business provides stable and predictable sales and cash flow. We sold more than 100 million vaccine doses in over 80 countries throughout the world, which makes us the largest independent vaccine player. Within vaccines we operate in three main markets: paediatric, travel and endemic, and respiratory.
Pipeline
We have a number of programs in various stages of development. Most of these are based on Crucell’s innovative PER.C6® technology.
Technologies
We have five core technologies; of which PER.C6® technology is Crucell’s most important proprietary technology. With over 60 commercial licenses issued on PER.C6® technology, Crucell has set new industry standards for the development and industrial-scale manufacturing of vaccines, recombinant proteins including monoclonal antibodies, and gene therapy products.
Products
Paediatric:
Quinvaxem® vaccine against five important childhood diseases.
Epaxal® Junior aluminum-free hepatitis A vaccine for children.
Hepavax-Gene® vaccine against hepatitis B.
MoRu-Viraten® vaccine against measles and rubella.
Travel and Endemic:
Epaxal® aluminum-free hepatitis A vaccine.
Vivotif® oral typhoid vaccine.
Dukoral® oral cholera vaccine.
Respiratory:
Inflexal® V virosomal adjuvanted influenza vaccine.
Research & Development
Vaccines in development:
- Yellow fever
- Influenza seasonal1
- Tuberculosis
- Malaria
- Ebola and Marburg
- HIV
Human antibodies in development:
- Rabies antibody combination
- Influenza antibodies H1 & H5
- 1
- Developed by sanofi pasteur using PER.C6®
Technologies
PER.C6® human designer cell line for the development and large-scale manufacturing of biopharma products.
AdVac® used in combination with PER.C6®, to develop recombinant vaccines.
MAbstract® applied for discovery of novel drug targets and identification of human antibodies.
STAR® designed to enhance production yields of recombinant human antibodies and proteins on mammalian cell lines.
Virosome a vehicle enabling the use of virus antigens in the making of vaccines.